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New Treatment Strategies in the Treatment of Juvenile Idiopathic Arthritis
Juvenil İdiopatik Artrit Tedavisinde Yeni Tedavi Yöntemleri
İbrahim GÖKÇE, Erkan DEMİRKAYA
Department of Pediatric Nephrology and Rheumatology, Gülhane Military Medical School, Ankara, Turkey

Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in childhood with an incidence
of 10-19/100.000 children below the age of 16 years, and
it is also one of the major causes of acquired disability
and impairment of quality of life in childhood. Early and
aggressive control of arthritis is essential to prevent
long-term disability. Methotrexate (MTX) provides clinical
benefits in JIA with an acceptable profile of toxic effects.
Nevertheless, in many cases, inefficacy, especially in
patients with polyarticular and systemic-onset form of JIA
(SOJIA) or intolerance to MTX, has led investigators to
try other therapeutic options. Biologic agents have been
designed to target key cytokines implicated in JIA including
tumor necrosis factor-α (TNF-α), Interleukin-1 (IL-1), IL-6
as well as signaling molecules involved in the regulation of
T-cell and B-cell lympocyte responses. Up to now, the U.S.
Food and Drug Administration (FDA) has approved three
biologic agents for use in moderate to severe polyarticular
JIA: etanercept, adalimumab and abatacept. In general,
TNF-α inhibitors are more beneficial for children with
polyarticular disease, and the biological agents that target
IL-1 and IL-6 activity appear to be successful also in treating
patients with SOJIA. The T-cell costimulation modulator,
abatacept, was shown to be effective for the treatment
of patients with moderate to severe polyarticular JIA.
Autologous stem cell transplantation has also been used in
patients with refractory JIA; however, the procedure carries
the risk of treatment-related high morbidity and mortality.
The purpose of this review is to summarise the recent
advances in the treatment of JIA.

Juvenil idiyopatik artrit (JİA), 16 yaş altı çocuklarda
10-19/100.000 düzeyinde bir insidansla çocukluk
çağının en yaygın kronik romatizmal hastalığıdır ve
aynı zamanda, bu yaş grubunda edinilmiş fonksiyon
yetersizliklerinin ve hayat kalitesinde bozulmanın önemli
nedenlerindendir. Erken ve agresif artrit tedavisi kalıcı
fonksiyon yetersizliğini önlemede önemlidir. Metotreksat
(MTX) JİA’da kabul edilebilir bir toksik etki profiliyle
faydalar sağlamaktadır. Bununla beraber MTX’in özellikle
poliartiküler ve sistemik başlangıçlı JİA hastalarında etkili
olmaması ve MTX intoleransı araştırmacıları diğer tedavi
seçeneklerini denemeye yöneltmiştir. Biyolojik ajanlar
JİA patogenezinde sorumlu tutulan interlökin-1 (İL-1),
İL-6 ve yanı sıra tümör nekrozis faktör-α (TNF-α) gibi kilit
sitokinleri ve T ve B lenfosit yanıtının düzenlenmesinde
rol alan sinyal moleküllerini hedef alır. Amerikan Gıda ve
İlaç Dairesi (FDA) şimdiye kadar orta seviyeli ila ciddi
poliartiküler JİA’da kullanılmak üzere üç biyolojik ajana
onay vermiştir. Bu ajanlar etanersept, adalimumab ve
abataseptir. Genel olarak TNF-α inhibitörleri poliartiküler
hastalığı olan çocuklarda daha faydalıdır ve İL-1 ve İL-6
aktivitesini hedef alan biyolojik ajanlar sistemik başlangıçlı
JİA’lı hastalarda da başarılı gibi görünmektedir. T hücresi
ko-stimülasyon düzenleyicisi abataseptin orta dereceli
ila şiddetli poliartiküler JİA’lı hastaların tedavisinde
etkiliolduğu gösterilmiştir. Dirençli JİA hastalarında
otolog kök hücre nakli de kullanılmıştır ancak bu işlem
tedaviyle ilişkili yüksek bir morbidite ve mortalite riski
taşımaktadır. Bu derlemede JİA tedavisindeki son
ilerlemelerin özetlenmesi amaçlanmıştır.
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Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in childhood with an
incidence of 10-19/100.000 children below the age of 16

years, and it is also a major cause of acquired disability
and impairment of quality of life in childhood.[1-5] The
term JIA, like its predecessors juvenile rheumatoid
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arthritis and juvenile chronic arthritis, is an umbrella
term for clinical patterns of arthritis in children.[6]
By definition JIA encompasses a group of clinically
heterogenous arthritides that begin prior to age 16
years, are of unknown cause,and present with joint
pain, stiffness and swelling that persists for longer than
six weeks.[1,7] According to the International League of
Associations for Rheumatology (ILAR) classification,
JIA is subdivided into seven categories which are
different from each other and from adult rheumatoid
arthritis (RA).[8,9] The ILAR classification is based
on the number of joints affected, the presence or
absence of specific serologic findings and systemic
manifestations as outlined in table 1.
Without appropriate treatment, JIA may result in
devastating consequences. Children may experience
permanent disability from joint destruction, growth
deformities or blindness. In the case of the systemiconset form of JIA (SOJIA), untreated disease may
even result in multiple organ failure and death.[7]
Although the outcome for children who have JIA has
improved in recent years, it is still less than ideal.[10]
Traditionally, the overall prognosis has been thought
to be good with up to 60% of cases entering remission
before adulthood,[5,10] but newer studies have not been
performed to address this issue. Various studies have
shown that 25% to 70% of children with JIA will still
have ongoing, active disease 10 years after onset[10,11]

and ≤35% of patients, regardless of the category of JIA,
demonstrated a state of disease inactivity of 12 months
or longer while off their medication regimen.[12] These
studies indicate that many patients diagnosed with
JIA will be exposed to extended periods of medication
throughout their lifetimes.
Conventional therapy consists of disease-modifying
antirheumatic drugs (DMARDs), such as methotrexate
(MTX), as the most common first-line DMARD and
non-steroidal anti-inflammatory drugs (NSAIDs),
with the avoidance of systemic corticosteroids. More
recently, intra-articular corticosteroid injections have
been included in the treatment approach, especially
in patients with oligoarthritis. Only MTX has proven
to be effective and safe in large controlled trials.[13]
Nevertheless, in many cases, inefficacy, especially in
patients with polyarticular and SOJIA or intolerance
to MTX, has led investigators to try other treatment
regimens. Prior to the era of biologicals, more than 25%
of polyarticular and nearly 50% of systemic patients
with JIA at five years after onset had functional
limitations, and two-thirds had radiographically
evident damage.[14] Because none of the available drugs
has curative potential, the primary therapeutic goals
are to control symptoms, to normalize joint function
and to avoid long-term joint damage.[15] The approach
to treatment depends on the assessment of individual
needs and the disease subtype. Other comorbidities,

Table 1. Classification of juvenile idiopathic arthritis
Category

Characteristics

Systemic onset

Arthritis in one or more joints, two weeks of fever, plus one or more of rash, lymphadenopathy,
hepatosplenomegaly

Oligoarthritis

Arthritis affecting one to four joints for the first six months of disease. After the first six months;
Persistent oligoarthritis: affecting four or fewer joints throughout the disease course
Extended oligoarthritis: affecting more than four joints after six months of disease

Polyarthritis,
Rheumatoid factor (–)

Arthritis affecting five or more joints during the first six months of the disease
Rheumatoid factor negative

Polyarthritis,
Rheumatoid factor (+)

Arthritis affecting five or more joints during the six months of the disease
Rheumatoid factor positive two or more times, at least three months apart

Psoriatic arthritis

Arthritis plus psoriasis or
Arthritis plus two of the following: dactylitis, nail pitting or onycholysis, psoriasis in a
first-degree relative

Enthesitis-related arthritis

Arthritis and enthesitis or
Arthritis or enthesitis plus two of the following: sacroiliac joint involvement, HLA-B27
positive, arthritis in a male >6 years of age, acute anterior uveitis, ankylosing spondylitis,
inflammatory bowel disease with sacroiliitis, Reiter’s syndrome or acute anterior uveitis in a
first-degree relative

Undifferentiated arthritis

Arthritis does not fulfill criteria for one of the above categories or
Arthritis fitting more than one of the above categories

Adapted from ILAR (9).
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Table 2. Pediatric core set criteria for improvement in juvenile idiopathic arthritis[16]
Criteria

1.
2.
3.
4.
5.
6.

Number of active joints
Number of joints with limited range of motion
Physician’s global assessment
Parent’s global assessment
Functional ability (Childhood health assessment questionnaire)
Erythrocyte sedimentation rate

American College of
Rheumatology Pediatric 30
response (ACR Pedi 30)

A minimum of 30% improvement in at least three out of six components, and a worsening of no
more than 30% in one component

ACR Pedi 50

A minimum of 50% improvement in at least three out of six components, and a worsening of no
more than 30% in one component

ACR Pedi 70

A minimum of 70% improvement in at least three out of six components, and a worsening of no
more than 30% in one component

such as the presence of uveitis, may influence treatment
decisions. The present article will provide a brief
update of clinical trial results and focus on recent
evidence on the safety and efficacy of biologicals in the
treatment of JIA.

This definition includes six parameters, all of which
have to be satisfied for a patient to be considered to
have ID. However, they were modified recently and
three changes were made to the provisional criteria
(Table 3).[18]

Prior to the development of the pediatric core set
and the American College of Rheumatology Pediatric
30 response criteria (ACR Pedi 30) in 1997, there had
been no single, uniform definition of improvement
for use in clinical trials of JIA(Table 2).[16] The ACR
Pedi 30 is used as the primary outcome measure for
trials of biologic agents and second line therapies.
Though not formally prospectively evaluated, the
ACR Pedi 20, 50, 70, and 90 measures are also used
as outcome measures in pediatric trials. The primary
goal in the management of JIA is the achievement and
maintenance of remission. Clinical criteria defining
the disease state as inactive disease (ID) or clinical
remission (CR) was developed in 2004 (Table 3).[17]

Biologic agents have been designed to target key
cytokines implicated in JIA including tumor necrosis
factor-α (TNF-α), Interleukin-1 (IL-1), and IL-6 as well
as signaling molecules involved in the regulation of
T-cell and B-cell lymphocyte responses.[7] In general
TNF-α inhibitors are more beneficial for children with
polyarticular disease than in those with SOJIA.[19] This
difference may be due to different cytokines underlying
the inflammatory response for each subtype of
disease.[20] Interleukin-1 and IL-6 rather than TNF-α
may be the predominant proinflammatory cytokines
in SOJIA.[21-23] Thus, biological agents that target IL-1
and IL-6 activity appear to be more successful in
treating patients with SOJIA.

Table 3. Internationally accepted definitions for inactive disease and clinical remission in children with juvenile
idiopathic arthritis[17]
Criteria*

No joints with active arthritis
No fever, rash, serositis, splenomegaly or generalized lymphadenopathy
No active uveitis
Normal ESR or CRP (if both are tested, both must be normal)
Physician’s global assessment of disease activity indicates no disease activity

Inactive disease**

If the patient simultaneously meet all of the above criteria

Clinical remission on medication

If the patient demonstrate inactive disease consistently for at least six months while on
medication for treatment of JIA

Clinical remission off medication

If the patient demonstrate inactive disease consistently for at least six months while off
medication for treatment of JIA

*: Clinical criteria have been modified recently by Wallace et al.[18] and three changes were done to the provisional criteria. The physician’s global assessment
of disease activity (PGA) was modified to read ‘PGA of disease activity score of ≤0.5 cm on a 10 cm VAS (visual analog scale) or ≤0.5 on an ordinal scale’.
The erythrocyte sedimentation rate (ESR) was modified to read ‘within normal limits in the laboratory where tested or, if elevated, not attributable to
juvenile idiopathic arthritis (JIA)’. Duration of morning stiffness (DMS) was added to the criteria set and reads, ‘DMS ≤15 minutes’. **: Now referred to
as clinically inactive disease (CID).
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Table 4. Adverse effects of anti-TNF-α biological agents[27]
Injection site

Local erythema and swelling which usually subsides within 24 hours. For adalimumab
there is greater immediate pain at the site of injection when compared to etanercept

Infusion reactions

During infusion or within one hour following completion of an infusion of infliximab,
fever, chills, nausea, sensation of thoracic constriction, dyspnea, flushing, urticaria,
anaphylactic reaction

Developments of antibodies
that neutralise the drug

More common with infliximab, which is a chimeric mAb and the most immunogenic of
the anti-TNF-α biologicals

Development of newly induced
ANA and anti-dsDNA

More common with infliximab treatment

Increased risk of severe infections

E.g. sepsis, pneumonia, herpes simplex and zoster infection, pyelonephritis

Increased risk of opportunistic
infections

E.g. histoplasmosis or coccidioidomycosis

Reactivation of silent tuberculosis

–

New onset or exacerbation of
CNS demyelinating disorders

Depression, headache, vertigo, fatigue, hyperactivity, nervousness, anxiety, pain
amplification, panic attacks, anorexia nervosa, optic neuropathy, hypoglossal paralysis
that have been reported, especially in patients using etanercept

New onset of inflammatory
bowel diseases

–

Possible reactivation of chronic
iridocyclitis

–

Increased risk of malignancy
especially lymphoma

It is unclear whether these agents are associated with an increased risk of malignancy or not

Soft tissue infections

–

Adapted from Chang et al.[27]; TNF: Tumor necrosis factor; ANA: Anti-nuclear antibody; dsDNA: Anti-double stranded DNA; CNS: Central nervous system;
mAb: Monoclonal antibody.

TNF-α inhibitors in juvenile
idiopathic arthritis
Tumor necrosis factor-α is a proinflammatory cytokine.
Elevated TNF-α levels have been identified in plasma and
synovial fluid in patients with JIA[24] justifying that it is
a major contributor to the inflammatory synovitis and
joint damage in JIA. Tumor necrosis factor-α inhibitors
are biological agents that block the immunological
effects of this inflammatory mediator. Inhibitors of
TNF-α were evaluated for efficacy in controlling JIA and
have been shown to be highly effective in the treatment
of JIA patients whose disease has been unresponsive
to traditional therapies.[25,26] It has become common
practice to move directly to anti-TNF therapy for the
treatment of arthritis in children who have failed to
respond adequately to MTX or who have been unable
to tolerate MTX due to adverse effects.[27,28] There are
three TNF-α inhibitors available for clinical use in
the treatment of JIA: Etanercept (Enbrel), infliximab
(Remicade) and adalimumab (Humira).
Etanercept
Etanercept (Enbrel) is a soluble p75 TNF receptor
fusion protein coupled to the Fc (fragment crystallizable

region) fragment of immunoglobulin G1 (IgG1) that
acts competitively to inhibit the binding of both TNF-α
and TNF-β to their cell surface receptors. Etanercept
binds its target cytokine only when it is in serum and
lowers the quantity of free TNF-α available for the
maintenance of the inflammatory synovitis of JIA.
Etanercept is administered as a subcutaneous injection
1-2 times per week. The TNF inhibitor etanercept is
the first biological approved by the U.S. Food and Drug
Administration (FDA) for treatment of moderate to
severe polyarticular JIA in children aged two years and
older. It can be used alone or as an adjunct to MTX.
Tumor necrosis factor-α inhibitors, including
etanercept, appear to have a more rapid onset of
clinical effect than conventional DMARDs. In
general, clinical improvement should be seen within
4-12 weeks.[27,29] However, these biologicals have not
been shown to induce long-term clinical remission
while patients were off medication. In a multicenter,
randomized controlled trial (RCT), Lovell et al.[30]
enrolled 69 children aged 4 to 17 years with DMARDrefractory polyarticular JIA. In a three-month open
label phase, all patients received etanercept at a dose
of 0.4 mg/kg twice a week and nearly 75% of patients
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achieved an ACR Pedi 30. Dramatic improvements
were achieved within weeks after commencement
of therapy. Those patients who met the predefined
definition of response at three months were
randomized to continue etanercept or be switched to
a placebo for four months. In the double-blind part of
the study, 81% of the patients who were randomized
to a placebo demonstrated disease flare compared
with 28% of those who continued on etanercept.
Thus, in most children, etanercept’s effects cease
within a few weeks of its discontinuation. This study
also showed that etanercept produced significant
improvement in disease activity when used in the
absence of DMARDs and appeared to be less effective
in patients with SOJIA. Etanercept has demonstrated
sustained improvement in the signs and symptoms
of polyarticular-course JIA with an acceptable safety
profile in an open-label extension (OLE) of a RCT at
four and eight years.[31,32] At an eight-year follow-up,
an ACR Pedi 70 was achieved by 61% of patients.
A 2008 systematic review of synthetic and biologic
DMARD therapy for RA in adult patients concluded
that anti-TNF monotherapy was similar in efficacy
to treatment with MTX alone. The combination of an
anti-TNF agent with MTX reduced disease activity
more than did anti-TNF monotherapy or MTX alone.[33]
In children, nonrandomized open-label studies of the
TNF inhibitors etanercept and infliximab have shown
that these biologicals safely control active disease when
used in combination with traditional therapies.[34,35] In
2008, a German registry also provided information
on 431 children treated either with etanercept alone
or with the combination of etanercept and MTX. At
12 months of follow up, the number of patients with
JIA reaching a ACR Pedi 70 response was significantly
higher in the etanercept and MTX group than in the
etanercept monotherapy group.[36]
Etanercept can induce disease remission and prevent
both clinical and radiological disease progression with
significant improvements in symptoms, function and
quality of life.[37,38] In another small study, bone mineral
status improved in patients who had responded to and
continued etanercept treatment for more than one year.[39]
Currently, little is known about when or how to
stop etanercept in patients with JIA when a good
clinical response is reached. Prince et al.[40] suggest that
patients with JIA should meet the criteria of clinical
remission of medication for at least 1.5 years before
considering discontinuation of etanercept and then
taper off it carefully. In addition, issues such as whether
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etanercept should be used before MTX (faster onset of
action, possibly more effective and less toxic) remain to
be resolved. As more biologic agents become available
over the next decade, there may be dramatic changes in
our approach to the treatment of JIA.
Infliximab
Infliximab (Remicade) is a chimeric mouse-human
monoclonal antibody (mAb) that binds specifically to
human TNF-α with high affinity (mAbs have a higher
affinity for a given cytokine than do soluble receptors
like etanercept) and neutralises the biological activity
of TNF-α by inhibiting its binding to its receptor.[27] In
JIA, MTX must be added to infliximab to prevent the
development of neutralising antibodies to infliximab
that could reduce its therapeutic efficacy. Monoclonal
antibodies (infliximab and adalimumab) bind their
target not only when it is free in the serum (like
etanercept does), but also when it is bound to the cell
surface. They do not bind TNF-β. They have a higher
affinity for a given cytokine than do soluble receptors.
Like etanercept, they lower the quantity of TNF-α
available to maintain an inflammatory response.
İnfliximab is given as an intravenous infusion on a
monthly to eight-weekly timetable. İnfliximab has
FDA approval for use in adult RA, psoriasis and adult
and pediatric Crohn’s disease, but not in JIA.
In a multicenter RCT, Ruperto et al.[41] enrolled
122 children aged 4 to 17 years with polyarticular JIA
refractory to MTX and randomized patients to receive
infliximab (3 mg/kg/dose) or a placebo for 14 weeks.
After 14 weeks, all children received infliximab through
week 44. Patients received MTX plus infliximab
3 mg/kg through week 44, or MTX plus placebo for
14 weeks followed by MTX plus infliximab 6 mg/kg
through week 44. At 14 weeks, a higher proportion of
patients randomized to infliximab 3 mg/kg had an ACR
Pedi 30 response when compared with patients in the
placebo group, but this difference was not statistically
significant. By week 52, clinical responses meeting the
ACR Pedi 50 and ACR Pedi 70 criteria were reached by
70% and 52% of the patients respectively. There were
no statistically significant differences between the
infliximab dose groups. Ruperto et al.[42] also assessed
the long-term safety and efficacy of MTX plus two
infliximab dosages (3 mg/kg or 6 mg/kg) in a threeyear OLE. At week 204, the proportions of patients
achieving ACR-Pedi 30/50/70/90 response criteria and
inactive disease status were 44%, 40%, 33%, 24%,
and 13% respectively, and they concluded that in the
limited population of JIA patients remaining in the
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study through four years, infliximab was safe and
effective even though it was associated with a high
patient discontinuation rate.
One small observational study compared the
administration of infliximab to etanercept in children
with polyarticular JIA who had not responded to
conventional DMARDs and showed similar results
(ACR Pedi 50 improvement of 80 to 90 percent) in the
two groups after 12 months of treatment.[34]
One of the unique and distressing complications of
JIA is a chronic, non-granulamatous uveitis. Tynjälä
et al.[43] enrolled 45 patients to compare the efficacy of
infliximab with that of etanercept in the treatment of
chronic uveitis; 24 patients were receiving etanercept
and 21 were receiving infliximab. Patients who were
taking infliximab were more likely to improve than
those taking etanercept.[43] Richards et al.[44] and
Rajaraman et al.[45] each reported six cases of JIAassociated uveitis which were poorly responsive to
other therapies. These patients were then treated with
infliximab and had significant improvement under
this therapy. Recently, the results of a multinational
survey were reported. In this study etanercept was
used in 34 patients and infliximab in 25 patients. The
response to etanercept was favourable in about 50% of
the cases, moderate in about 15%, and poor in about
35%, and for infliximab the response was favourable
in about 69% of the cases, moderate in about 31%,
and poor in 0%.[46] These studies demonstrate that
infliximab is more effective than etanercept in the
treatment of refractory uveitis.
Adalimumab
Adalimumab (Humira) is a recombinant fully
human mAb which is administered either weekly
or, more commonly, every other week as a single
subcutaneous injection rather than by intravenous
infusion. Adalimumab is associated with a lower risk of
antibody formation compared with infliximab because
of its fully humanised structure. In 2008, adalimumab
was approved by the FDA as the second TNF-α inhibitor
for the treatment of moderate to severe JIA in patients
aged four years and older.
In a multicenter, randomized, medicationwithdrawal study, Lovell et al.[47] enrolled 171 children
aged 4 to 17 years with active polyarticular JIA.
Children were stratified according to MTX use and
received adalimumab subcutaneously every other week
for 16 weeks. In a manner similar to the etanercept trial,
after an open-label lead-in phase of 16 weeks, patients

with ACR Pedi 30 response were randomly selected
in a double blind manner to receive adalimumab or
a placebo for an additional 32 weeks. In the second
phase of the study, patients receiving adalimumab
had significantly fewer flare-ups than patients in the
placebo group regardless of whether they received
MTX or not. Adalimumab demonstrated sustained
improvement during two years of treatment. After 104
weeks of OLE treatment, the proportions of patients
achieving ACR-Pedi 50/70/100 response criteria were
86%, 77%, and 40%, respectively.
Eighteen patients with uveitis were treated with
adalimumab. The patients had all failed to respond
to systemic steroids, cyclosporin, MTX, leflunomide,
etanercept or infliximab. Sixteen out of 18 patients
had good responses to adalimumab.[48] In another
retrospective observational study by Tynjälä et al.,[49]
of 20 patients with chronic uveitis treated with
adalimumab, 19 of them had been previously treated
with infliximab or etanercept. Of the 20 patients, seven
showed improved activity, one showed worsening
activity, and twelve showed no change in the activity
of uveitis. The mean number of flares/year decreased
from 1.9 to 1.4 during adalimumab treatment, but this
change was not significant. These studies suggest that
adalimumab is a potential treatment option in JIAassociated uveitis, even in patients not responsive to
other previous anti-TNF therapies.
There is no clear evidence to support the superiority
of one TNF-α inhibitor over another and failure to
respond to one agent does not preclude response to
another.[50,51] In one small study, it was shown that
using a third anti-TNF agent, adalimumab, can be
efficacious in patients with JIA refractory to etanercept
and/or infliximab.
Adverse effects of anti TNF-α biological agents
In order to use TNF-α inhibitors appropriately, it
is important to be aware of potential treatment-related
adverse effects (AEs) of these biologicals and the
differences between them (Table 4). As well as with
other DMARDs, SOJIA is at a greater risk for AEs than
non-systemic JIA categories.
The most common AEs of TNF-α inhibitors are
injection site reactions to subcutaneously administered
drugs (etanercept and adalimumab) or infusion
reactions (IRs) with infliximab. The cutaneous
injection site reaction consists of local erythema and
swelling which usually subsides within 24 hours.
Transient injection site reactions are described in about
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39% of patients with JIA on etanercept.[30] In addition
to the adverse effects reported above, there is greater
immediate pain at the site of adalimumab injections
when compared to etanercept, but this is generally an
inconvenience that children find bearable.[47] Infusionrelated reactions were defined as any adverse event
that occurred during or within one hour following
completion of an infusion. Infusion reactions are the
most common AEs in patients treated with infliximab
(26-38%)[41,52] and the reason for withdrawal among
those receiving infliximab. These reactions are possibly
due to immune responses against the mostly humanized
mouse monoclonal antibody. In the international trial,
IRs occurred in approximately 26% and 32% of patients
from weeks 0-52 and 52-204 (OLE) respectively, with a
higher incidence in patients positive for antibodies to
infliximab, and were more frequent in patients treated
with the lower 3 mg/kg dosage than the 6 mg/kg
dose.[41,42] Serious IRs occurred in eight patients wherein
five patients had a possible anaphylactic reaction.
Gerloni et al.[52] enrolled 163 children (68 infliximab,
95 etanercept). In their trial, the greater number of
patients who presented AEs with infliximab (62.9%)
versus those with etanercept (54.3%) was due to IRs
(sensation of thoracic constriction, dyspnea, flushing,
urticaria). Infusion reactions were the most common
AEs (38.3%), and 20.1% of patients suspended treatment
because of severe IR relapse. In this study, 12 patients
receiving etanercept manifested a diffuse cutaneous
reaction that led to withdrawal in only two patients.
Most centers report a similarly increased incidence of
side effects in children treated with mAbs, especially
infliximab relative to etanercept. Since adalimumab
is also administered subcutaneously, but only every
other week, this mAb is at least administered as easily
as etanercept.
One of the major concerns with infliximab is
the development of human anti-chimeric antibodies
(HACA) that neutralise the drug, thereby limiting its
long-term efficacy or causing IRs. In an international
trial, 25% of all patients had antibodies to infliximab
with a higher incidence in the infliximab 3 mg/kg
group (38%) compared with the infliximab 6 mg/kg
group (12%).[41] Infliximab seems to be more frequently
responsible for newly induced anti-nuclear antibody
(ANA) and anti-double stranded DNA (anti-dsDNA)
antibody. During the OLE, newly positive ANA and
anti-dsDNA occurred in 26% and 7% of patients from
weeks 52-204.[42] However, only rare cases of druginduced systemic lupus erythematosus (SLE), discoid
lupus erythematosus (LE) and cutaneous vasculitis
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are described. In another international trial, Lovell et
al.[47] reported that approximately 16% of the patients
had anti-adalimumab antibodies. This percentage is
greater than the 5% observed during clinical trials of
adult patients with RA.[53] Positive anti-adalimumab
antibody tests were less frequent among those receiving
concomitant MTX than among those receiving
adalimumab monotherapy.
Serious adverse events (SAEs) are defined as events
that are fatal or life-threatening, require hospitalization
or prolong an existing hospitalization. SAEs cause
a persistent or significant disability or incapacity,
a congenital anomaly, or birth defect. Etanercept
offers an acceptable safety profile in long-term
treatments.[31] The long-term safety profile of etanercept
was maintained for up to eight years of continuous
drug use.[32] Exposure-adjusted rates of SAEs did not
increase over time, and the most common new SAEs
reported beyond four years of drug exposure were flare
or worsening of disease. Between the fourth and eighth
year of follow-up, a single case of pyelonephritis was
the only additional infection reported. It is thought
that the three TNF-α inhibitors will share a similar
long-term side effect.
The most important adverse effect of anti-TNF-α
therapy is the increased risk of severe infections (e.g.
sepsis, pneumonia, herpes simplex and zoster infection,
pyelonephritis). After four years of an international
trial of etanercept, the overall rate of SAEs was 0.13
and of serious infections was 0.04 per patient-year.[31]
The overall rate of SAEs (0.12 per patient-year) did
not increase with long-term exposure to etanercept.
Similarly, SAEs occured only in 14/171 patients, seven
of whom had serious infections in the adalimumab
trial.[47] In the infliximab trial, however, the overall rate
of SAEs (24/117) was higher, six of whom had serious
infections.[41] In addition, there may be an increased
risk of opportunistic infections, particularly fungal
(e.g. histoplasmosis or coccidioidomycosis) with the
use of these agents. In patients who develop serious
infections, the TNF-α blocker should be ceased, at least
until the complete resolution of the infection.[27] The
reactivation of silent tuberculosis (TB), definitely related
to TNF-α inhibition, has completely disappeared as TB
screening and prophylaxis are now the rule before antiTNF-α therapy.[52] Infliximab is associated with the
greater risk.[54]
Over an 11-year period (1998-2009), 48 cases of
malignancies in children with a TNF inhibitor have
been reported to the FDA Adverse Event Reporting
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System. Half of them were lymphomas, including
Hodgkin’s and non-Hodgkin’s lymphoma; the rest
included leukemia, melanoma, and solid organ
cancers. Therefore, the FDA concluded that there is
an increased risk of malignancy with TNF blockers.
However, due to the relatively rare occurrence of these
cancers, the limited number of pediatric patients
treated with TNF blockers, and the possible role of other
immunosuppressive therapies used concomitantly with
TNF blockers, the FDA is unable at this time to fully
characterize the strength of the association between
using TNF blockers and developing a malignancy.
New-onset or relapsing central nervous system (CNS)
demyelinating disorders and neuropsychiatric AEs
(depression, headache, vertigo, fatigue, hyperactivity,
nervousness, anxiety, pain amplification, panic attacks,
anorexia nervosa, optic neuropathy, hypoglossal
paralysis) have been reported, especially in patients
using etanercept.[52] New-onset inflammatory bowel
diseases (IBD) have also been detected in patients
treated with etanercept.[52] Another concern with
TNF-α blockers, especially with etanercept, is the
possible reactivation of chronic iridocyclitis (CIC).[52]
TNF-α inhibitors are effective in treating JIA and have
acceptable safety profiles, but because of all these
possible AEs, it is suggested that these biologic agents
be used in patients with severe disease that is refractory
to conventional therapy.
Interleukin-1 inhibitors
Interleukin-1 is a proinflammatory cytokine
that triggers the production of proinflammatory
prostoglandins as well as such other proinflammatory
cytokines as IL-6 and TNF-α. Pascual et al.,[23] reported
that IL-1 is a major mediator of the inflammatory
cascade that underlies SOJIA. This study demonstrated
that sera from patients with SOJIA could provoke IL-1
synthesis in tissue cultures of mononuclear cells from
healthy controls, and this cytokine represents a target
for therapy in this disease. Anakinra is currently in use
in children with JIA while several other IL-1 inhibitors
(rilonacept and canakinumab) are under investigation.
Anakinra
Anakinra (Kineret) is a recombinant IL-1 receptor
antagonist (IL-1 Ra) that is approved for use in RA.
Because of its short half-life, it is administered daily by
subcutaneous injection (1-2 mg/kg/day). The Anakinra
in Systemic-Onset Juvenile Idiopathic Arthritis
trial (ANAJIS trial) was the the only double-blind
RCT which tested anakinra efficacy in 24 patients
with refractory SOJIA. Preliminary results reported

in abstract form demonstrated that at one month,
there was a significant difference in the response rate
between patients treated with anakinra (8/12) and a
placebo (1/12). Ten patients from the placebo group
switched to anakinra at month one and nine were
responders at month two. Gene expression profile
analyses showed a set of gene pathways dysregulated in
SOJIA whose expression dramatically changed upon
anakinra treatment.[55]
The first report on the effectiveness of IL-1Ra in
SOJIA was presented in 2002. In an open-label study
by Reiff,[56] 80 patients with various forms of JIA were
treated with anakinra; patients with SOJIA had a
better response to anakinra than did those with other
types of JIA (11/15 responded to anakinra). A similar
recent RCT of anakinra (1mg/kg/day; maximum 100
mg/day) versus placebo in 50 patients with JIA by
Ilowite et al.[57] was unable to demonstrate significant
efficacy of the drug. Subgroup analysis, however,
showed that response rates may be higher among
patients with SOJIA. Recent case reports demonstrated
that treatment with IL-1 Ra (anakinra) led to rapid and
sustained remission within a few days following the
initiation of anakinra injections in patients with SOJIA
who had been resistant to conventional DMARDs
including TNF-blockade.[21,58-60] An initial case series
reported by Pascual et al.[23] reported a dramatic
response to IL-1 blockade among SOJIA patients with
six out of nine patients treated with anakinra achieving
complete remission and two having improvement in
symptoms. The results obtained in this case series
support the use of anakinra as second-line therapy
in children with SOJIA who have failed to respond to
standard therapy.
Lequerré et al.[61] recently described 20 SOJIA patients
treated with anakinra and found marked and sustained
improvement in less than half of the cases. Similarly,
Gattorno et al.[62] described a variable response of
patient’s arthritis to anakinra in their series of 22
cases. In addition, Zeft et al.[63] reported that arthritis
was less improved compared with the general systemic
symptoms of the disease. These observations indicate
that although anakinra is considered to be effective in
SOJIA, there is a group of patients who are anakinraresistant. The blockade of IL-1 signalling has a dramatic
and sustained effect in some patients with the cessation
of symptoms and a significant decrease of acute phase
markers. The large group of partial responders and
non-responders are suggestive of pathological processes
that are independent of the IL-1 pathway.[64,65]
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Injection site reactions (itch and/or erythema) and
injection pain with daily subcutaneous medication are
frequent local effects of anakinra[60,61,63] which may be so
severe as to require the stoppage of medication. In the
study by Zeft et al.,[63] over half of the patients reported
localized pain or swelling at their injection sites.
Similar to TNF-α inhibitors, IL-1 blockade increases
the risk of infections. Anakinra is not recommended
in a combined regimen with a TNF inhibitor because
of an increased frequency of serious adverse events,
including serious infections.[66] In the ANAJIS trial,
eight patients discontinued anakinra before month 12.
Two patients (both on placebos) had painful injections
during the double-blind phase, one had ileocolic
symptoms leading to the diagnosis of Crohn’s disease,
and one had a case of transient hepatic cytolysis.
There was also a lack of efficacy or a disease flare in
four cases.[55] Varicella, localized herpes, leishmaniasis
and EBV infections have been described in children
with SOJIA receiving anakinra.[61,63] Three cases of
macrophage activation syndrome (MAS) have also
been described.[62,63] Anakinra has also been used to
sufficiently treat MAS in SOJIA patients.[67,68] Without
well-designed trials, the attributability of these findings
remains unclear, and the ultimate long-term safety
profile of anakinra needs to be determined.
Rilonacept
Rilonacept (IL-1 Trap/Arcalyst) is a long-acting IL-1
blocker currently undergoing trials in children with
SOJIA. Rilonacept is a recombinant fusion protein that
combines IL-1 receptor protein components with the
Fc portion of the human immunoglobulin molecule.
Unlike anakinra, which requires daily dosing,
rilonacept is administered once a week.[7] Preliminary
results of a double-blind, placebo-controlled study
of rilonacept (2.2 to 4.4 mg/kg/week) in SOJIA were
reported by Lovell et al.[69] in abstract form. Of the 21
patients enrolled in the trial, 12 remain in the openlabel study and have had good responses to rilonacept
with 10 patients achieving an ACR Pedi 70 response
at 42 weeks. Six out of seven patients who had failed
to respond to anakinra were found to improve on
rilonacept. Adverse events were mild or moderate in
severity included generalized rash and mood alteration.
SAEs included exacerbation of pancytopenia and MAS.
The OLE study on rilonacept in SOJIA was presented
at the ACR 2009 meeting. In this long-term OLE study,
sustained responses were observed in clinical and
laboratory assessments in over 50% of patients with
SOJIA at two years. There was a significant reduction
in daily prednisone dosage. No deaths, malignancies, or
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serious infections occurred. The authors suggested that
chronic IL-1 blockade with rilonacept was generally
safe and well-tolerated.[70]
Canakinumab
Canakinumab (ACZ885) is a fully humanized mAb
which binds specifically to the β isoform of IL-1
(IL-1β) and neutralizes the bioactivity of human IL-1β.
It is administered as either a subcutaneous injection
or an intravenous infusion. Canakinumab shows
encouraging efficacy and is well tolerated in children
with SOJIA according to a new phase II study presented
at PReS 2009, a joint congress with the 2009 Congress
of the European League Against Rheumatism (EULAR)
in Copenhagen, Denmark. This open-label staggered
dose-escalation study assessed 23 children with active
disease receiving a single subcutaneous injection of
canakinumab in the dose range 0.5-9 mg/kg. Of those
patients who responded to treatment (59% of initial
enrollers), 100% achieved the ACR Pedi 50 score within
only 15 days of receiving canakinumab. Adverse events
were predominantly mild to moderate in severity
and included infections and gastrointestinal disorders.
SAEs including worsening nausea in a patient with
a medical history of gastritis and EBV infection in
another patient relating to canakinumab resolved
during treatment. Early clinical trials have established
the administration of canakinumab every two weeks to
be safe and effective offering a considerable advantage
over existing treatment with anakinra which must be
injected daily and which is often poorly tolerated by
patients.[71]

IL-6 inhibitor: tocilizumab
Tocilizumab (Roactemra/Actemra/MRA) is a
recombinant humanized monoclonal antibody that
acts as an IL-6 receptor antagonist that has not yet
been approved by the FDA for the treatment of RA
or JIA. Interleukin-6 has both proinflammatory
and anti-inflammatory effects. Plasma levels of IL-6
have been demonstrated to correlate with disease
activity in JIA patients, and particularly elevated
IL-6 levels have been noted in patients with SOJIA.[24]
In general, patients with SOJIA have a higher rate of
treatment failure with TNF-α inhibitors than those
with other chronic arthritis subtypes indicating
that TNF-α is not the only cytokine implicated in
the pathogenesis of the disease.[72] Although it is
likely that the blockade of IL-1 has a dramatic and
sustained effect in some patients with SOJIA, the
large group of partial responders and non-responders
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suggests pathological processes independent of the
IL-1 pathway.[64] Therapy with an anti-IL-6-receptor
antibody (tocilizumab) revealed much better
response rates in two phase II studies in SOJIA[73,74]
and, more recently, in poly- and oligoarticular onset
disease.[75] A randomized clinical trial is needed
to define efficacy and to identify the proper target
population. This response rate is likely to be due
to the fact that IL-6 can be stimulated by IL-1 and
TNF; therefore, a blockade of IL-6 will take care of
processes that come mainly from the IL-1 or TNF
pathways as well other sources of stimulation of IL-6
in this disease.[64]
In a phase III trial by Yokota et al.,[76] 56
children (aged 2-29 years) with SOJIA refractory to
conventional treatment were given three doses of
tocilizumab 8 mg/kg every two weeks as intravenous
infusions during a six week open-label lead-in phase.
The trial design was similar to the etanercept trial.
Patients who achieved ACR Pedi 30 response and
C-reactive protein concentration (CRP) of less than
5 mg/L were randomly assigned to receive a placebo
or continue tocilizumab treatment for 12 weeks.
Patients responding to tocilizumab and needing
further treatment were enrolled in an OLE phase
for at least 48 weeks. After the end of the openlabel phase, ACR Pedi 30, 50, and 70 responses
were achieved by 51 (91%), 48 (86%) and 38 (68%) of
patients respectively. Forty-three patients continued
to the double-blind phase. Four (17%) of the 23
patients in the placebo group compared to 16 (80%) of
the 20 patients in the tocilizumab group maintained
an ACR Pedi 30 response and a CRP concentration
of less than 15 mg/L. ACR Pedi 30, 50, 70 responses
were achieved by 47 (98%), 45 (94%) and 43 (90%)
of 48 patients, respectively. SAEs occured in 13 of
50 patients during the OLE phase. These included
anaphylactoid reactions, gastrointestinal hemorrhages
and bronchitis.
Interleukin-6 may also play a role in complications
of SOJIA such as growth impairment, systemic
osteoporosis and amyloidosis.[77] In this respect, in a
small group of SOJIA patients, cartilage oligomeric
matrix protein (COMP) levels were found to be lower
than controls and they markedly increased under
tocilizumab therapy. These findings suggested that
in SOJIA patients, the growth cartilage turnover was
suppressed during the active disease phase, but it
improved in the remission phase after tocilizumab
treatment.[78]

Turk J Rheumatol

T-cell costimulation modulator;
Abatacept
Abatacept (Orencia/CTLA4-Ig) is a fully human,
soluble fusion protein with a unique mechanism of
action. Abatacept consists of the extracellular domain
of the cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4) and the Fc portion of the immunoglobulin
G1 (IgG1). CTLA4-Ig binds with either CD80 (B7-1)
or CD86 (B7-2) on antigen-presenting cells, thereby
acting as a competitive inhibitor of the CD28-B7
costimulatory interaction and preventing the second
activation signal received by T cells via CD28. Abatacept
thus downregulates T-cell stimulation and potentially
affects many downstream cytokines and cell types that
have been implicated in the pathogenesis of JIA.
In 2008, abatacept was approved by the FDA for
treatment of patients aged six years or older with
moderate to severe polyarticular JIA. The European
Medicines Agency (EMEA) also recently (2010)
approved abatacept in combination with MTX for the
treatment of moderate to severe polyarticular JIA in
pediatric patients six years of age and older as a second
line biologic after TNF inhibitors. Abatacept has been
studied in a double-blind, randomized controlled
withdrawal trial including 190 children aged 6-17 years
old with active polyarticular JIA refractory to at least one
previous DMARD agent including anti-TNF agents.[79]
The design of this pivotal study was similar to trials
of the anti-TNF agents (etanercept and adalimumab)
and tocilizumab. All patients were given 10 mg/kg of
abatacept intravenously in the open-label period of four
months. At the end of the open-label treatment period,
two-thirds of the 190 enrolled patients had improved by
30% or more according to ACR Pedi response criteria.
Of the patients who did respond to abatacept, 60 were
randomly assigned to receive 10 mg/kg abatacept at
28-day intervals for six months, and 62 were randomly
assigned to receive a placebo. Flares of arthritis occured
in 33 of 62 (53%) patients receiving placebo and 12 of 60
(20%) patients receiving abatacept (p=0.0003). During
the double-blind period, there was no difference in the
frequency of AEs between the two groups. Few SAEs
were reported with no serious infections, opportunistic
infections, or serious autoimmune disorders.
Abatacept was also used in a case of refractory
JIA uveitis resistant to infliximab and rituximab, and
the response was good.[80] Abatacept may be a useful
alternative for treating JIA children with associated
uveitis and must, therefore, be considered as a viable
treatment option.
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Other agents
Rituximab
Rituximab (MabThera/Rituxan), a selective B-celldepleting agent, is a chimeric anti-CD20 mAb. B
lymphocytes have been implicated in the pathogenesis
of rheumatoid synovitis. The precise role of B cells
has not been elucidated, but potential mechanisms
include an antigen-presenting function, secretion of
proinflammatory cytokines and costimulation of T
cells. In this context, B cell depletion with rituximab
has recently emerged as a potential treatment option
for patients with RA. In randomized controlled studies,
rituximab has been shown to be effective in patients
with RA[81,82] and approved by the FDA for treatment of
adult patients with moderate to severe RA. There are
few published case reports on the use of rituximab in
children with refractory JIA.[83-85] On the other hand, in
an oral presentation at the 3rd Europaediatrics Congress
2008, Alexeyeva et al.[86] reported on 33 patients (16 boys
and 17 girls) with severe systemic (n=24) or articular
(n=9) JIA refractory to immunosuppressive therapy
including oral and parenteral glucocorticoids treated
with rituximab. In this study, 24 patients refractory
to TNF-α blockers and rituximab had been shown
to produce a marked therapeutic effect including a
decrease in clinical and laboratory disease activity
parameters. They suggested that rituximab might be a
promising therapeutic option in severe refractory JIA.
Thus, further RCTs are needed to clarify the role of
rituximab in children with severe refractory JIA.
Thalidomide
Thalidomide (thalomid) is a synthetic derivative of
glutamic acid (alpha-phthalimido-glutarimide) with
teratogenic, immunomodulatory, anti-inflammatory
and anti-angiogenic properties. Thalidomide acts
primarily by inhibiting both the production of TNF-α
in stimulated peripheral monocytes and the activities
of interleukins and interferons. This agent also inhibits
polymorphonuclear chemotaxis and monocyte
phagocytosis. Preliminary studies have demonstrated
that thalidomide may be beneficial for children with
severe SOJIA.[87,88] Lehman et al.[87] reported the use
of thalidomide in the dose range 2 to 5 mg/kg/day
administered orally in 13 children with refractory
SOJIA. Ten of the 13 children had improved by 50% or
more according to ACR Pedi response criteria. In an
another small study, García-Carrasco et al.[88] reported
three cases of recalcitrant SOJIA that had improved
dramatically after treatment with thalidomide. The
most serious toxicity associated with thalidomide is its
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documented human teratogenicity. Based on present
knowledge, thalidomide must not be used at any time
during pregnancy. Somnolence, dizziness, and rash are
the most commonly observed AEs associated with the
use of thalidomide. Thalidomide is also associated with
peripheral neuropathy and neutropenia.
Leflunomide
Leflunomide (Arava), an orally administered
inhibitor of pyrimidine synthesis, has been shown to
be a safe and effective long-term therapy for adults
with RA.[89] In a multinational RCT, Silverman et al.[90]
enrolled 94 children aged 3 to 17 years to compare the
safety and efficacy of oral leflunomide with oral MTX in
the treatment of polyarticular JIA. At week 16, the rates
of ACR Pedi 50 responses were 60% in the leflunomide
group and 77% in the MTX group (p=0.10), and the
rates of ACR Pedi 70 responses were 43% and 60%
respectively (p=0.14). In both groups, the improvements
achieved at week 16 were maintained at week 48.
After 48 weeks of treatment, MTX and leflunomide
both resulted in high rates of clinical improvement,
and the ACR pedi 30, 50, and 70 responses were
similar between the two groups (79%, 76%, and 70%
for leflunomide, and 91%, 86%, and 83% for MTX).
The incidence of treatment-related AEs was similar
in the leflunomide group and the MTX group. The
most commonly reported AEs were gastrointestinal
symptoms including liver function test abnormalities,
headache, nasopharyngeal symptoms, and reversible
alopecia. Like thalidomide, leflunomide is also a known
teratogen, so women of childbearing potential must not
be started on leflunomide until pregnancy is excluded.

Autologous stem cell
transplantation (ASCT)
Autologous stem cell transplantation has been used in
patients with severe resistant JIA. For children with
severe disease who fail to achieve disease control despite
the use of multiple drugs including anti-TNF and antiIL-6 receptor treatment, both allogenic and ASCT
may offer an alternative option for disease remission.
However, the procedure still carries a high mortality
rate for an illness that does not typically have a fatal
outcome. Results from 34 children with refractory
SOJIA (29 children) and polyarticular disease who have
undergone ASCT at multiple centers across Europe
have been published.[91] Data demonstrated 18/34 (53%)
patients had a complete response, six showed a partial
response, and seven did not respond. The incidence of
infectious complications was high and three children
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died. All deaths occured in patients with SOJIA due to
MAS complicated by infection. Autologous stem cell
transplantation protocols were subsequently modified
in 1999 to decrease the depletion of T-cells. After these
changes, there have been no ASCT-related deaths
among 11 patients who have received the modified
regimen.[92] Although this procedure has helped a
number of children whose disease was intractable,
the authors point to the risk of high treatment-related
morbidity and mortality. It is hoped that with the help
of more effective anticytokine treatments such highrisk procedures will not be necessary in the future.
In conclusion, juvenile idiopathic arthritis is the
most common rheumatic childhood disease that
is associated with significant morbidity including
functional disability and ocular damage. Prior to the
era of biologicals, more than 25% of polyarticular and
nearly 50% of systemic patients with JIA had functional
limitations, and two-thirds had radiographically
evident damage five years after onset. New and exciting
alternative medications are emerging for children
resistant to standard therapy. New data from large
RCTs have showed the efficacy of TNF-α inhibitors,
the T-cell costimulation modifier abatacept, and
leflunomide for the treatment of polyarticular JIA.
Anti-IL-1 and anti-IL-6 biologicals, particularly for
SOJIA patients, look very promising as well. The
mAbs to TNF-α appear to be more effective in treating
chronic uveitis associated with JIA than etanercept;
however, treatment still needs to be developed. The
hope is that recent changes in treatment approaches
will result in marked improvement in long-term
functional outcomes of patients with JIA.
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